收藏切换
Advances in the treatment of high-risk and recurrent or refractory neuroblastoma with disialoganglioside monoclonal antibody
收藏切换
Xiaojun YUAN
World Clinical Drug | 2022, 43(8) : 967 - 974
Less
收藏切换
World Clinical Drug | 2022, 43(8): 967-974
• Topic •
Advances in the treatment of high-risk and recurrent or refractory neuroblastoma with disialoganglioside monoclonal antibody
Full
Xiaojun YUAN
Affiliations
  • Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
Published: 2022-08-10 doi: 10.13683/j.wph.2022.08.002
Outline
收藏切换

The prognosis of pediatric neuroblastoma (NB) is highly heterogeneous, the long-term survival rate of high-risk or recurrent or refractory NB patients remains less than 50%. Disialoganglioside (GD2) is highly expressed in NB cells, but limited expression in normal tissues. Therefore, GD2 monoclonal antibody (mAb) therapy has become a specific immunotherapy for high-risk and recurrent or refractory NB patients. GD2 mAb binds to GD2 antigen to form immune complex, which plays antitumor effects by inducing antibody-dependent and complement-dependent immune mechanisms. GD2 mAb can significantly improve the survival rate of high-risk and recurrent or refractory NB patients, but attention should be paid to the management of adverse reactions in different groups during treatment. The timing of GD2 mAb combined with chemotherapy, as well as the benefits and risks combined with immune checkpoint inhibitors programmed cell death protein-1/programmed cell death 1 ligand-1, iodine-131-labeled metaiiodo-benzylguanidine or chimeric antigen receptor T cells should be explored. This article reviewed the research progress of GD2 mAb in the treatment of high-risk or recurrent or refractory NB in children in recent years, in order to provide some reference for clinical treatment.

disialoganglioside monoclonal antibody  /  high-risk  /  recurrent  /  refractory  /  neuroblastoma  /  immunotherapy
袁晓军. 双唾液酸神经节苷脂单克隆抗体治疗儿童高危和复发/难治性神经母细胞瘤研究进展. 世界临床药物, 2022 , 43 (8) : 967 -974 . DOI: 10.13683/j.wph.2022.08.002
Xiaojun YUAN. Advances in the treatment of high-risk and recurrent or refractory neuroblastoma with disialoganglioside monoclonal antibody[J]. World Clinical Drug, 2022 , 43 (8) : 967 -974 . DOI: 10.13683/j.wph.2022.08.002
Year 2022 volume 43 Issue 8
9
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.08.002
  • Receive Date:2022-05-05
  • Online Date:2026-11-19
  • Published:2022-08-10
Article Data
Affiliations
History
  • Received:2022-05-05
Affiliations
    Department of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.08.002
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT